Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
Book cover Arzneiverordnungs-Report 2009

  • 930 Accesses

Zusammenfassung

In der Therapie rheumatischer Erkrankungen einschließlich degenerativer Veränderungen werden vorzugsweise nichtsteroidale Antiphlogistika eingesetzt (Abbildung 16.1). Mit ihnen gelingt es, den entzündlichen Prozess zurückzudrängen, die Beweglichkeit zu verbessern und den entzündlichen Schmerz zu vermindern. Für Glucocorticoide (vgl. Kapitel 21) sind in der Therapie der rheumatoiden Arthritis in den letzten Jahren die Indikationen für eine niedrig dosierte Therapie ausgeweitet worden. Die remissionsinduzierenden antirheumatischen Arzneimittel („Disease-modifying antirheumatic drugs“, früher auch als „Basistherapeutika“ bezeichnet) haben mengenmäßig nur einen geringen, jedoch im Verlauf der letzten Jahre kontinuierlich steigenden Anteil an den Verordnungen der Antirheumatika und Antiphlogistika. Unter ihnen erfahren neuerdings vor allem die gentechnologisch hergestellten TNFα-Antagonisten einen besonders starken Verordnungszuwachs. Rheumasalben und Einreibungen sind aufgrund ihrer Rezeptfreiheit in der Regel von der Verordnung zu Lasten der gesetzlichen Krankenversicherung seit 2004 ausgenommen und deshalb nur noch mit drei Präparaten vertreten.

Verordnungen von nichtsteroidalen Antiphlogistika, COX-2-Hemmern und Remissionsinduktoren 1999 bis 2008. Gesamtverordnungen nach definierten Tagesdosen

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): „Aus der UAW-Datenbank“: Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequenzen für ihre künftige Verordnung. Dtsch Ärztebl 101, A 3365.

    Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528.

    Article  CAS  PubMed  Google Scholar 

  • Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1–15.

    Article  CAS  PubMed  Google Scholar 

  • Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102.

    Google Scholar 

  • Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al (2001): Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53: 343–353.

    Article  CAS  PubMed  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781.

    Article  CAS  PubMed  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110.

    Article  CAS  PubMed  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 869.

    Article  PubMed  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421.

    Article  CAS  PubMed  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29:1581–1582.

    PubMed  Google Scholar 

  • DeAngelis CD, Fontanarosa PB (2008): Impugning the integrity of medical science. The adverse effects of industry influence. JAMA 299: 1833–1835.

    Article  CAS  PubMed  Google Scholar 

  • DeWitt DL (1999): Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55:625–631.

    CAS  PubMed  Google Scholar 

  • Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). PflÜgers Arch 76: 306–318.

    Article  CAS  Google Scholar 

  • Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106–2111.

    Article  CAS  PubMed  Google Scholar 

  • Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321: 181–190.

    Article  CAS  PubMed  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea.eu.int/htms/hotpress/d6275705.htm

    Google Scholar 

  • European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf

    Google Scholar 

  • FDA Alert for Healthcare Professionals (2005): Valdecoxib (marketed as Bextra). Publiziert am 7. April 2005 unter: www.fda.gov/bbs/topics/news/2005/NEW01171.html

    Google Scholar 

  • FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html

    Google Scholar 

  • Food and Drug Administration (2004): FDA Public Health Advisory: Safety of Vioxx. Publiziert am 30. September 2004 unter: www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm

    Google Scholar 

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740.

    CAS  PubMed  Google Scholar 

  • Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005): Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481.

    CAS  PubMed  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262.

    CAS  PubMed  Google Scholar 

  • Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit J Pharmacol 123: 927–935.

    Article  CAS  Google Scholar 

  • Hawkey CJ (1999): COX-2 inhibitors. Lancet 353: 307–314.

    Article  CAS  PubMed  Google Scholar 

  • Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 43: 370–377.

    Article  CAS  PubMed  Google Scholar 

  • Jüni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J 324: 1287–1288.

    Article  PubMed  Google Scholar 

  • Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005): Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157–164.

    CAS  PubMed  Google Scholar 

  • Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776–783.

    Article  CAS  PubMed  Google Scholar 

  • Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD et al (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075–1052.

    Article  Google Scholar 

  • Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929–1933.

    Article  CAS  PubMed  Google Scholar 

  • Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324–326.

    Article  CAS  PubMed  Google Scholar 

  • Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J und die Kommission Pharmakotherapie der DGRh (2007): Neufassung der Empfehlungen der Kommission Pharmakotherapie der DGRh. Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 66: 72–75.

    Article  CAS  PubMed  Google Scholar 

  • Meyer R (2005): Pfizer nimmt Bextra vom Markt. Dtsch Ärztebl 102: A 1023.

    Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693–11697.

    Article  CAS  PubMed  Google Scholar 

  • Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959.

    Article  CAS  PubMed  Google Scholar 

  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verbürg KM (2005): Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091.

    Article  CAS  PubMed  Google Scholar 

  • Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxygenase-2 in gastric mucosal defense. Life Sci 69: 2993–3003.

    Article  CAS  PubMed  Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

    Google Scholar 

  • Psaty BM, Kronmal RA (2008): Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. A case study based on documents from rofecoxib litigation. JAMA 299: 1813–1817.

    Article  CAS  PubMed  Google Scholar 

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759–766.

    Article  CAS  PubMed  Google Scholar 

  • Ross JS, Hill KP, Egilman DS, Krumholz HM (2008): Guest authorship and ghostwriting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. Jama 299: 1800–1812.

    Article  CAS  PubMed  Google Scholar 

  • Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group (2004): Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674.

    Article  CAS  PubMed  Google Scholar 

  • Shi S, Klotz U (2008): Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233–252.

    Article  CAS  PubMed  Google Scholar 

  • Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000): Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284: 1247–1255.

    Article  CAS  PubMed  Google Scholar 

  • Smolen JS, Kalden JR, Scott DJ, Rozman B, Kvien TK, Larsen A et al. for the European Leflunomide Study Group (1999): Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353: 259–266.

    Article  CAS  PubMed  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080.

    Article  CAS  PubMed  Google Scholar 

  • Solomon DH, Schneeweiss S, Glynn RJ, Kiota Y, Levin R, Mogun H, Avorn J (2004): Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073.

    Article  CAS  PubMed  Google Scholar 

  • Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235.

    CAS  PubMed  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Böger, R.H., Schmidt, G. (2009). Antirheumatika und Antiphlogistika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2009. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01080-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01080-4_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01079-8

  • Online ISBN: 978-3-642-01080-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation